For decades, respiratory testing followed a centralized model: collect a sample, transport it to the central lab and process in batches, with results frequently not known before the patient leaves. Ultra-rapid, CLIA-waived molecular platforms are transforming near-patient diagnosis and care, while reshaping laboratory operations by altering staffing models, governance structures, and evolving the role of clinical laboratories.
Faster decisions within a single patient encounter
In emergency and urgent care settings, the clinical impact of point-of-care (POC) molecular testing is real. Research has found that rapid molecular testing for respiratory viruses cut median turnaround time from over 26 hours to under 3 hours, reduced hospital admissions, and increased the number of patients receiving results before leaving in the studied population. These improvements supported earlier isolation, faster clinical decision-making, and timelier treatment, all within a single patient visit.
New modes of POC molecular testing are also eliminating several workflow steps. Transport time from the health clinic to the lab is eliminated when testing happens at the point of collection. Of note, central labs often wait for batches of samples before running tests, adding even more delays on the backend. Delays can be reduced when a nurse can hand a patient their result in as soon as 10 minutes in some cases, depending on the platform and assay, after sample collection, rather than requiring clinicians to retrieve results in the laboratory information center (LIS) later. Modern chemistries are designed to withstand common inhibitors, often bypassing nucleic acid extraction altogether, enabling direct-from-swab testing with significantly faster results.
What the CLIA waiver changes for molecular testing
Generally speaking, the CLIA waiver designation is a key enabler of testing in patient care settings. To qualify, a test must meet FDA criteria demonstrating minimal procedural steps, a low risk of incorrect results and automated results of interpretation. This makes the test easy and reliable enough for less-credentialed staff across urgent care clinics, pharmacies, and clinician offices, including those stretched thin by staffing shortages.
In certain clinical scenarios, waived molecular platforms may reduce the need for a confirmatory culture or laboratory-based molecular testing to rule out an infection, depending on the specific test’s validated performance and intended use. Now a single result can lead to immediate action. A recent study found that POC molecular testing in community pharmacies reduced unnecessary antibiotic usage for viral infections, reinforcing antibiotic stewardship and the importance of finding the right diagnosis at the point of care.
The central lab as the command center
As high-volume respiratory testing moves to decentralized settings, the central laboratory's role shifts from production to oversight. Lab leadership is often responsible for validating decentralized assays, ensuring continuity across sites, and building programs to support quality and operator training at various care settings.
POC molecular testing also has the potential to help free up skilled personnel at the central lab to operate at the top of their license, focusing on complex molecular profiling, oncology diagnostics, and antimicrobial resistance work that requires their time and expertise.
Integration, quality, and reimbursement challenges
Moving molecular workflows into less controlled environments has the potential to introduce risk that central labs otherwise manage carefully. At the top of the list is contamination. A single contamination event can generate a series of false positives that compromise workflows, adding time and effort in clean up, investigation, and staff retraining. Modern molecular technologies utilize contained cartridge designs to help mitigate that risk. Ensuring clinical staff administer the test consistently and in accordance with manufacturer instructions for use is also critical, and that becomes harder when managing multiple locations rather than a single team of specialized lab technicians.
On the data and reimbursement side, POC results that do not flow into the health system's LIS require manual reconciliation for billing, adding burden, and error risk. Coverage can also be inconsistent, and health systems have to think about the right test, at the right time, in the right setting, and whether their payers will cover it.
As molecular diagnostics move closer to patients, the promise is faster, more informed clinical decision-making. This can be achieved best when decentralized testing is supported by appropriate central laboratory oversight, integrated data infrastructure, and alignment between clinical value and reimbursement. The health systems that may thrive will be those that treat POC molecular testing as an extension of the central laboratory—not a replacement for it. That approach can free central labs to focus on complex, high-value work while supporting a distributed testing system. However, uncertainty in healthcare funding remains a critical variable in how quickly and sustainably these innovations can be implemented at scale.
